Search research articles
Contact Us
Filters
Showing results (171-180 of 192) with videos related to
Page
of 20
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
March 4, 2019
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations
Cindy Neuzillet, Andrea Casadei Gardini, Bertrand Brieau, et al.
The Lancet Regional Health. Europe
|
March 17, 2025
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe
Lorenza Rimassa, Angela Lamarca, Grainne M O'Kane, et al.
The American Journal of Gastroenterology
|
January 21, 2015
Impact of chromoscopy on adenoma detection in patients with Lynch syndrome: a prospective, multicenter, blinded, tandem colonoscopy study
Gabriel Rahmi, Thierry Lecomte, David Malka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 5, 2024
Management of intrahepatic and perihilar cholangiocarcinomas: Guidelines of the French Association for the Study of the Liver (AFEF)
Cindy Neuzillet, Marie Decraecker, Hélène Larrue, et al.
The Oncologist
|
September 5, 2024
Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer
Emeric Boisteau, Laetitia Dahan, Nicolas Williet, et al.
The Lancet. Oncology
|
May 24, 2014
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
David Malka, Pascale Cervera, Stéphanie Foulon, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2019
FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial
David Malka, Eric François, Frédérique Penault-Llorca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 17, 2024
Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study
Christelle De La Fouchardière, David Malka, Claire Cropet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2019
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study
Julien Edeline, Meher Benabdelghani, Aurélie Bertaut, et al.
Nature Cell Biology
|
February 7, 2018
Tumour spheres with inverted polarity drive the formation of peritoneal metastases in patients with hypermethylated colorectal carcinomas
Olivier Zajac, Joel Raingeaud, Fotine Libanje, et al.
Page
of 20
Search research articles
Search
Showing results (171-180 of 192) with videos related to
Sort By:
Page
of 20
European Journal of Cancer (Oxford, England : 1990)
|
March 4, 2019
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations
Cindy Neuzillet, Andrea Casadei Gardini, Bertrand Brieau, et al.
The Lancet Regional Health. Europe
|
March 17, 2025
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe
Lorenza Rimassa, Angela Lamarca, Grainne M O'Kane, et al.
The American Journal of Gastroenterology
|
January 21, 2015
Impact of chromoscopy on adenoma detection in patients with Lynch syndrome: a prospective, multicenter, blinded, tandem colonoscopy study
Gabriel Rahmi, Thierry Lecomte, David Malka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 5, 2024
Management of intrahepatic and perihilar cholangiocarcinomas: Guidelines of the French Association for the Study of the Liver (AFEF)
Cindy Neuzillet, Marie Decraecker, Hélène Larrue, et al.
The Oncologist
|
September 5, 2024
Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer
Emeric Boisteau, Laetitia Dahan, Nicolas Williet, et al.
The Lancet. Oncology
|
May 24, 2014
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
David Malka, Pascale Cervera, Stéphanie Foulon, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2019
FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial
David Malka, Eric François, Frédérique Penault-Llorca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 17, 2024
Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study
Christelle De La Fouchardière, David Malka, Claire Cropet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2019
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study
Julien Edeline, Meher Benabdelghani, Aurélie Bertaut, et al.
Nature Cell Biology
|
February 7, 2018
Tumour spheres with inverted polarity drive the formation of peritoneal metastases in patients with hypermethylated colorectal carcinomas
Olivier Zajac, Joel Raingeaud, Fotine Libanje, et al.
Page
of 20